Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer

Published:2018-01-10 Issue:5 Volume:14 Page:e399-e404
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Hamid Anis A.¹^ORCID,Willson Kaspar¹,Vincent Andrew D.²,Tamjid Babak¹,Lee Margaret³,Bergin Alice⁴,Gan Chun⁵,Campbell Ainsley¹,Stewart Josephine¹,Pezaro Carmel³,Tran Ben⁴⁵⁶,Weickhardt Andrew J.¹

Affiliation:

1. Olivia Newton-John Cancer Wellness and Research Center; Austin Hospital; Heidelberg Victoria Australia

2. Freemasons Foundation Center for Men's Health; Discipline of Medicine; University of Adelaide; Adelaide South Australia Australia

3. Eastern Health and Monash University Eastern Health Clinical School; Box Hill Victoria Australia

4. Epworth Freemasons; East Melbourne Victoria Australia

5. Royal Melbourne Hospital; Parkville Victoria Australia

6. Peter MacCallum Cancer Center; Victorian Comprehensive Cancer Center; Parkville Victoria Australia

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.12840/fullpdf

Reference26 articles.

1. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study;Berthold;Clin Cancer Res,2008

2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

3. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

4. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials;Templeton;Ann Oncol,2013

5. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial;Kellokumpu-Lehtinen;Lancet Oncol,2013

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel;Supportive Care in Cancer;2023-05

2. Prevention of docetaxel‐associated febrile neutropenia with primary granulocyte colony‐stimulating factor in Chinese metastatic hormone‐sensitive and castration‐resistant prostate cancer patients;Asia-Pacific Journal of Clinical Oncology;2021-04

3. The impact of a tailored follow-up intervention on comprehensive geriatric assessment in older patients with cancer - a randomised controlled trial;Journal of Geriatric Oncology;2021-01

4. Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer;Cancer Chemotherapy and Pharmacology;2020-04-02